Hypofractionated radiotherapy of patients with glioblastoma: the first experience in Ukraine and prospects view

Authors

DOI:

https://doi.org/10.25305/unj.270580

Keywords:

neoplasms, glioblastoma, radiotherapy, radiation dose hypofractionation, survival analysis

Abstract

Objective: To assess the survival of patients (pts) with newly diagnosed glioblastoma (GBM) in groups with hypofractionated regime radiotherapy, standard fractionationated regime radiotherapy and whole brain irradiation.
Materials and methods: A retrospective non-randomized single-center study of 205 pts with GBM grade 4 according to the WHO classification treated in Romodanov Neurosurgery Institute named after Acad. A.P. Romodanov National Academy of Medical Science of Ukraine (2014–2020). The mean age of pts 53.8 years (95% CI 52.1 - 55.5); there were 114 men (55.6%) and 91 women (44.4%). According to the regimen radiotherapy (RT), pts were divided into 3 groups: 49 (23.9%) pts (standard RT: 2.0 Gy per fraction in 30 fractions, total dose 60.0 Gy) – group "sRT", 110 (53.7%) pts (hypofractionated RT: 3.5 Gy per fraction in 15 fractions, total dose 52, 5 Gy) - group "hRT", 46 (22.4%) pts – group "WBRT" (whole brain radiation). Differences in progression-free survival (PFS) and overall survival (OS) between the three groups were analyzed using Kaplan–Meier survival curve, log-rank test and Pearson Chi-square test.
Results: The median OS is 15,0 (95% CI 14,1 – 17,1), 16,5 (95% CI 14,1 – 18,8) and 8,7 (95% CІ 7,5 – 9,5) months for sRT, hRT and WBRT, respectively. There is a significant difference in OS for sRT and hRT compared to WBRT (p=0.00000), without difference in OS between sRT and hRT (p=0.06757). The median PFS in sRT and hRT does not differ significantly: sRT – 9.0 (95% CI 9.0 - 10.0) months; hRT – 9.0 (95% CI 8.0 - 10.0) months. The median OS for WBRT is 5.1 (95% CI 4.0 - 6.0) months. There is a significant difference in PFS for sRT and hRT compared to the WBRT (p=0.00000), without difference in PFS between sRT and hRT (p=0.43374). The risk of death for WBRT compared to sRT is 2.5 times higher (HR 2.5 [95% CI, 1.45 - 4.46)) and 3.5 times higher compared to the hRT group (HR 3.5 [95% CI, 2.09-5.88)). The risk of progression for WBRT is 2.8 times higher (HR 2.78 [95% CI, 1.63-4.74)) compared to sRT, and 3.1 times higher (HR 3.12 [95% CI, 1.91-5.10)) compared to hRT.
The broad implementation of hRT into clinical practice is specific to all modern radiation oncology. This trend is currently underway due to the specific positive clinical effects of hRT, which are discussed in detail in our publication.
Conclusions: Our study demonstrates comparable survival outcome between sRT and hRT groups. This is an argument in favor of the feasibility of using hRT as a part of multimodal GBM treatment in terms of oncological outcomes. Further studies are needed to identify specific stratification groups of GMB patients with the greatest survival and quality of life benefits due to hRT.

Author Biographies

Andrey B. Gryazov, Romodanov Neurosurgery Institute, Kyiv

Department of Radioneurosurgery

Oleksandr Y. Glavatskyi, Romodanov Neurosurgery Institute, Kyiv

Department of Adjuvant Treatment of CNS Tumors

Olga Y. Chuvashova, Romodanov Neurosurgery Institute, Kyiv

Department of Neuroradiology and Radioneurosurgery

Oksana V. Zemskova, Romodanov Neurosurgery Institute, Kyiv

Department of Radioneurosurgery

Olena G. Andriichenko, Romodanov Neurosurgery Institute, Kyiv

Department of Radioneurosurgery

Iryna V. Kruchok, Romodanov Neurosurgery Institute, Kyiv

Department of Radioneurosurgery

Andrii A. Griazov, Romodanov Neurosurgery Institute, Kyiv

Department of Radioneurosurgery

Igor P. Spasichenko, Romodanov Neurosurgery Institute, Kyiv

Department of Radioneurosurgery

Hennadii V. Khmelnytskyi, Romodanov Neurosurgery Institute, Kyiv

Intracerebral Tumors Department

Iryna M. Shuba, Romodanov Neurosurgery Institute, Kyiv

Neurobiochemistry Department

Volodymyr A. Stuley, Institute for Applied Systems Analysis (IASA), National Technical University of Ukraine “Igor Sikorsky Kyiv Polytechnic Institute”Kyiv

Department of Artificial Intelligence

References

1. Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016. Neuro Oncol. 2019 Nov 1;21(Suppl 5):v1-v100. [CrossRef] [PubMed] [PubMed Central]

2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005 Mar 10;352(10):987-96. [CrossRef] [PubMed]

3. Walker MD, Alexander E Jr, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, Norrell HA, Owens G, Ransohoff J, Wilson CB, Gehan EA, Strike TA. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg. 1978 Sep;49(3):333-43. [CrossRef] [PubMed]

4. Burton E, Yusuf M, Gilbert MR, Gaskins J, Woo S. Failure to complete standard radiation therapy in glioblastoma patients: Patterns from a national database with implications for survival and therapeutic decision making in older glioblastoma patients. J Geriatr Oncol. 2020 May;11(4):680-687. [CrossRef] [PubMed] [PubMed Central]

5. Minniti G, Amelio D, Amichetti M, Salvati M, Muni R, Bozzao A, Lanzetta G, Scarpino S, Arcella A, Enrici RM. Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide. Radiother Oncol. 2010 Dec;97(3):377-81. [CrossRef] [PubMed]

6. Weller M, Cloughesy T, Perry JR, Wick W. Standards of care for treatment of recurrent glioblastoma--are we there yet? Neuro Oncol. 2013 Jan;15(1):4-27. [CrossRef] [PubMed] [PubMed Central]

7. Minniti G, Niyazi M, Alongi F, Navarria P, Belka C. Current status and recent advances in reirradiation of glioblastoma. Radiat Oncol. 2021 Feb 18;16(1):36. [CrossRef] [PubMed] [PubMed Central]

8. Wick W, Osswald M, Wick A, Winkler F. Treatment of glioblastoma in adults. Ther Adv Neurol Disord. 2018 Jul 25;11:1756286418790452. [CrossRef] [PubMed] [PubMed Central]

9. Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G, Bendszus M, Balana C, Chinot O, Dirven L, French P, Hegi ME, Jakola AS, Platten M, Roth P, Rudà R, Short S, Smits M, Taphoorn MJB, von Deimling A, Westphal M, Soffietti R, Reifenberger G, Wick W. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2021 Mar;18(3):170-186. [CrossRef] [PubMed] [PubMed Central]

10. Amelio D, Lorentini S, Schwarz M, Amichetti M. Intensity-modulated radiation therapy in newly diagnosed glioblastoma: a systematic review on clinical and technical issues. Radiother Oncol. 2010 Dec;97(3):361-9. [CrossRef] [PubMed]

11. Trone JC, Vallard A, Sotton S, Ben Mrad M, Jmour O, Magné N, Pommier B, Laporte S, Ollier E. Survival after hypofractionation in glioblastoma: a systematic review and meta-analysis. Radiat Oncol. 2020 Jun 8;15(1):145. [CrossRef] [PubMed] [PubMed Central]

12. Hanna C, Lawrie TA, Rogozińska E, Kernohan A, Jefferies S, Bulbeck H, Ali UM, Robinson T, Grant R. Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis. Cochrane Database Syst Rev. 2020 Mar 23;3(3):CD013261. [CrossRef] [PubMed] [PubMed Central]

13. Nassiri F, Taslimi S, Wang JZ, Badhiwala JH, Dalcourt T, Ijad N, Pirouzmand N, Almenawer S, Stupp R, Zadeh G. Determining the Optimal Adjuvant Therapy for Improving Survival in Elderly Patients with Glioblastoma: A Systematic Review and Network Meta-analysis. Clin Cancer Res. 2020 Jun 1;26(11):2664-2672. [CrossRef] [PubMed]

14. Guo L, Li X, Chen Y, Liu R, Ren C, Du S. The efficacy of hypofractionated radiotherapy (HFRT) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: A meta-analysis. Cancer Radiother. 2021 Apr;25(2):182-190. [CrossRef] [PubMed]

15. Melo SM, Marta GN, Latorraca COC, Martins CB, Efthimiou O, Riera R. Hypofractionated radiotherapy for newly diagnosed elderly glioblastoma patients: A systematic review and network meta-analysis. PLoS One. 2021 Nov 4;16(11):e0257384. [CrossRef] [PubMed] [PubMed Central]

16. Rodin D, Tawk B, Mohamad O, Grover S, Moraes FY, Yap ML, Zubizarreta E, Lievens Y. Hypofractionated radiotherapy in the real-world setting: An international ESTRO-GIRO survey. Radiother Oncol. 2021 Apr;157:32-39. [CrossRef] [PubMed] [PubMed Central]

17. Atun R, Jaffray DA, Barton MB, Bray F, Baumann M, Vikram B, Hanna TP, Knaul FM, Lievens Y, Lui TY, Milosevic M, O'Sullivan B, Rodin DL, Rosenblatt E, Van Dyk J, Yap ML, Zubizarreta E, Gospodarowicz M. Expanding global access to radiotherapy. Lancet Oncol. 2015 Sep;16(10):1153-86. [CrossRef] [PubMed]

18. Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D, Graham J, Kirkbride P, Logue J, Malik Z, Money-Kyrle J, O'Sullivan JM, Panades M, Parker C, Patterson H, Scrase C, Staffurth J, Stockdale A, Tremlett J, Bidmead M, Mayles H, Naismith O, South C, Gao A, Cruickshank C, Hassan S, Pugh J, Griffin C, Hall E; CHHiP Investigators. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016 Aug;17(8):1047-1060. [CrossRef] [PubMed] [PubMed Central]

19. Malmström A, Grønberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, Abacioglu U, Tavelin B, Lhermitte B, Hegi ME, Rosell J, Henriksson R; Nordic Clinical Brain Tumour Study Group (NCBTSG). Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012 Sep;13(9):916-26. [CrossRef] [PubMed]

20. Perry JR, Laperriere N, O'Callaghan CJ, Brandes AA, Menten J, Phillips C, Fay M, Nishikawa R, Cairncross JG, Roa W, Osoba D, Rossiter JP, Sahgal A, Hirte H, Laigle-Donadey F, Franceschi E, Chinot O, Golfinopoulos V, Fariselli L, Wick A, Feuvret L, Back M, Tills M, Winch C, Baumert BG, Wick W, Ding K, Mason WP; Trial Investigators. Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. N Engl J Med. 2017 Mar 16;376(11):1027-1037. [CrossRef] [PubMed]

21. Gregucci F, Surgo A, Bonaparte I, Laera L, Ciliberti MP, Carbonara R, Gentile MA, Giraldi D, Calbi R, Caliandro M, Sasso N, D'Oria S, Somma C, Martinelli G, Surico G, Lombardi G, Fiorentino A. Poor-Prognosis Patients Affected by Glioblastoma: Retrospective Study of Hypofractionated Radiotherapy with Simultaneous Integrated Boost and Concurrent/Adjuvant Temozolomide. J Pers Med. 2021 Nov 4;11(11):1145. [CrossRef] [PubMed] [PubMed Central]

22. Chidley P, Shanker M, Phillips C, Haghighi N, Pinkham MB, Whittle JR, Sia J. Moderately hypofractionated versus conventionally fractionated radiation therapy with temozolomide for young and fit patients with glioblastoma: an institutional experience and meta-analysis of literature. J Neurooncol. 2022 Nov;160(2):361-374. [CrossRef] [PubMed] [PubMed Central]

23. Rothwell PM. External validity of randomised controlled trials: "to whom do the results of this trial apply?". Lancet. 2005 Jan 1-7;365(9453):82-93. [CrossRef] [PubMed]

24. McKee M, Britton A, Black N, McPherson K, Sanderson C, Bain C. Methods in health services research. Interpreting the evidence: choosing between randomised and non-randomised studies. BMJ. 1999 Jul 31;319(7205):312-5. [CrossRef] [PubMed] [PubMed Central]

25. Kuss O, Blettner M, Börgermann J. Propensity Score: an Alternative Method of Analyzing Treatment Effects. Dtsch Arztebl Int. 2016 Sep 5;113(35-36):597-603. [CrossRef] [PubMed] [PubMed Central]

26. Lalani N, Jimenez RB, Yeap B. Understanding Propensity Score Analyses. Int J Radiat Oncol Biol Phys. 2020 Jul 1;107(3):404-407. [CrossRef] [PubMed]

27. Lederman M. The early history of radiotherapy: 1895-1939. Int J Radiat Oncol Biol Phys. 1981 May;7(5):639-48. [CrossRef] [PubMed]

28. Mould RF. Invited review: the early years of radiotherapy with emphasis on X-ray and radium apparatus. Br J Radiol. 1995 Jun;68(810):567-82. [CrossRef] [PubMed]

Downloads

Published

2023-03-27

How to Cite

Gryazov, A. B., Glavatskyi, O. Y., Chuvashova, O. Y., Zemskova, O. V., Andriichenko, O. G., Kruchok, I. V., Griazov, A. A., Spasichenko, I. P., Khmelnytskyi, H. V., Shuba, I. M., & Stuley, V. A. (2023). Hypofractionated radiotherapy of patients with glioblastoma: the first experience in Ukraine and prospects view. Ukrainian Neurosurgical Journal, 29(1), 38–47. https://doi.org/10.25305/unj.270580

Issue

Vol. 29 No. 1 (2023)

Section

Original articles

License

Copyright (c) 2023 Andrey B. Gryazov, Oleksandr Y. Glavatskyi, Olga Y. Chuvashova, Oksana V. Zemskova, Olena G. Andriichenko, Iryna V. Kruchok, Andrii A. Griazov, Igor P. Spasichenko, Hennadii V. Khmelnytskyi, Iryna M. Shuba, Volodymyr A. Stuley

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Ukrainian Neurosurgical Journal abides by the  CREATIVE COMMONS copyright rights and permissions for open access journals.

Authors, who are published in this Journal, agree to the following conditions:

1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the Journal under the terms of Creative Commons Attribution License, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this Journal.

2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form of which it has been published by the Journal (for example, to upload the work to the online storage of the Journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this Journal is included.